



15 May 2023

LungLife AI, Inc.
("LungLife" or the "Company")

Block Listing Six Monthly Return

LungLife AI (AIM: LLA1), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

Name of applicant:	LungLife AI, Inc.		
Name of scheme:	1. 2010 Stock Incentive Plan 2. 2020 Stock Incentive Plan 3. 2021 Omnibus Long-Term Incentive Plan		
Number and class of securities originally admitted:	1,356,139 common shares of US \$0.0001 each		
Date of admission:	15 November 2021		
Period of return:	From:	15 November 2022	To: 15 May 2023
Balance of unallotted securities under scheme(s) from previous return:	1. 475,583 2. 201,374 3. 673,990		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	1. NIL 2. NIL 3. NIL		
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	1. NIL 2. NIL 3. NIL		
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:	1. 475,583 2. 201,374 3. 673,990		
Total number of securities in issue at the end of the period	25,485,982		
Name of contact:	David Anderson, Chief Financial Officer		
Telephone number of contact:	+44 (0)20 7933 8780 or lunglifeai@walbrookpr.com		

For further information please contact:

LungLife AI, Inc.
Paul Pagano, CEO
David Anderson, CFO

www.lunglifeai.com
Via Walbrook PR

Investec Bank plc (Nominated Adviser & Broker)
Virginia Bull / Cameron MacRitchie / Lydia Zychowska

Tel: +44 (0)20 7597 5970

Goodbody (Joint Broker)
Tom Nicholson / Stephen Kane

Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420

Walbrook PR Limited
Alice Woodings / Phillip Marriage

Tel: +44 (0)20 7933 8780
or LungLifeAI@walbrookpr.com
Mob: 07407 804 654 / 07867 984 082

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB[®] test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.